Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination

• DOI: 10.1371/journal.pone.0139062
• Publication Date: 2015-09-23T18:02:34Z
• Authors: Ellinor Östensson; Maria Fröberg; Amy Leval; Ann-Cathrin Hells...; Magnus Bäcklund; Niklas Zethraeus; Sonia Andersson
• Keywords: Genital warts

Objective Costs associated with HPV-related diseases such as cervical dysplasia, cancer, and genital warts have not been evaluated in Sweden. These costs must be estimated order to determine the potential savings if these were eradicated assess combined cost-effectiveness of HPV vaccination cancer screening. The present study aimed estimate prevention, management, treatment from a societal perspective Sweden 2009, 1 year before quadrivalent program was implemented. Methods Materials Data Swedish screening used calculate prevention (cytological screening), management (colposcopy biopsy following inadequate/abnormal cytological results), CIN. official statistics cancer. Published epidemiological data number incident, recurrent, persistent cases warts; clinical expert panel assessed procedures. Estimated visits, procedures, use medications annual cost warts. Results From perspective, total 2009 €106.6 million, which €81.4 million (76%) direct medical costs. CIN €74 million; for women normal inadequate cytology alone accounted 76% this sum. incident prevalent palliative care €23 million. recurrent €9.8 Conclusion Prevention, are substantial. Defining is important future analyses